GPGareth R. Price

Gareth R. Price

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gareth R. Price has a total of 180 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Microbiology Galaxy Lab: a community-driven gateway for reproducible and FAIR analysis of microbiological data

    by Engy M. T. Nasr, Nikolaos Pechlivanis, Nikolaos Strepis, Pierre Amato, Matthias Bernt, Anshu Bhardwaj, Daniel Blankenberg, Daniela Brites, Fabio Cumbo, Katherine T. Do, et al.

    The explosion of microbial omics data has outpaced the ability of many researchers to analyse it, with complex tools and limited computational resources creating barriers to discovery. To address this gap, we present the Microbiology Galaxy Lab (MGL): a free, globally accessible, community-supported platform that combines state-of-the-art analytical power with user-friendly accessibility. Supported by the Galaxy and global microbiology communities, this platform integrates over 315 tool suites and 115 curated workflows, enabling comprehensive metabarcoding, (meta)genomic, (meta)transcriptomic, and (meta)proteomic data analysis within a FAIR-aligned environment. It also supports research in the health and infectious disease sectors, as well as in environmental microbiology. The platform’s utility is exemplified through various use cases, including antimicrobial resistance tracking, biomarker prediction, microbiome classification, and functional annotation of key microbes. Built on reproducibility and community engagement, it supports the creation, sharing, and updating of best-practice workflows. Over 35 tutorials and learning paths empower scientists, fostering an ecosystem that keeps resources at the forefront of microbiological data analysis. The MGL enables collective analysis, democratising research, thereby accelerating discovery across the global microbiology community ( microbiology.usegalaxy.org , .eu , .org.au , . fr ).

  • Open Access

    Community-curated Galaxy interfaces with the Galaxy Labs Engine

    by Cameron J Hyde, Anna Syme, Bérénice Batut, Paul F Zierep, Winnie Mok, Wendi A Bacon, Gareth R Price

    The Galaxy platform is a globally distributed environment for data-intensive research, providing thousands of analysis tools across major public servers. However, this decentralised ecosystem presents usability challenges for both users and administrators, particularly in surfacing relevant tools and workflows for specific communities. To improve discoverability and support global collaboration, the Galaxy project has employed community-driven “Galaxy Flavours”—subdomains with curated content for defined research domains. While conceptually valuable, Flavours suffer from critical limitations: they are statically deployed, difficult to replicate across servers, and often provide inconsistent and unintuitive user interfaces. To address these challenges, we developed the Galaxy Labs Engine (GLE), a service that enables the creation of Galaxy Labs. This new paradigm enables globally synchronised, domain-specific entry points built from structured, reusable web content. GLE separates content from deployment, allowing communities to define a shared canonical representation of their domain, while enabling individual Galaxy servers to locally customise presentation. Labs are designed to guide users through curated tools, workflows, and training resources, and are aimed at researchers who are new to the analytical methods or technologies specific to the domain. The Galaxy Labs Engine provides a consistent, customisable, and community-driven interface layer for the Galaxy ecosystem. By fostering FAIR principles, Labs offer a scalable improvement to Flavours and enhance Galaxy’s ability to support diverse research communities. GLE is open-source and currently deployed at https://labs.usegalaxy.org.au, with multiple Labs already supporting active user groups. This work strengthens Galaxy’s role as a collaborative platform for reproducible, user-centered science.


  • Open Access

    Community-Curated Galaxy Interfaces with the Galaxy Labs Engine

    by Cameron J. Hyde, Anna Syme, Bérénice Batut, Paul F. Zierep, Winnie Mok, Wendi A. Bacon, Gareth R. Price

    The Galaxy platform is a globally distributed environment for data-intensive research, providing thousands of analysis tools across major public servers. However, this decentralised ecosystem presents usability challenges for both users and administrators, particularly in surfacing relevant tools and workflows for specific communities. To improve discoverability and support global collaboration, the Galaxy project has employed community-driven "Galaxy Flavours"—subdomains with curated content for defined research domains. While conceptually valuable, Flavours suffer from critical limitations: they are statically deployed, difficult to replicate across servers, and often provide inconsistent and unintuitive user interfaces.To address these challenges, we developed the Galaxy Labs Engine (GLE), a service that enables the creation of Galaxy Labs. This new paradigm enables globally synchronised, domain-specific entry points built from structured, reusable web content. GLE separates content from deployment, allowing communities to define a shared canonical representation of their domain, while enabling individual Galaxy servers to locally customise presentation. Labs are designed to guide users through curated tools, workflows, and training resources, and are aimed at researchers who are new to the analytical methods or technologies specific to the domain.The Galaxy Labs Engine provides a consistent, customisable, and community-driven interface layer for the Galaxy ecosystem. By fostering FAIR principles, Labs offer a scalable improvement to Flavours and enhance Galaxy’s ability to support diverse research communities. GLE is open-source and currently deployed at https://labs.usegalaxy.org.au, with multiple Labs already supporting active user groups. This work strengthens Galaxy’s role as a collaborative platform for reproducible, user-centered science.


  • Open Access

    Microbiology Galaxy Lab: The first community-driven gateway for reproducible and FAIR analysis of microbial data

    by Engy Nasr, Nikos Pechlivanis, Nikolaos Strepis, Pierre Amato, Matthias Bernt, Anshu Bhardwaj, Daniel Blankenberg, Daniela Brites, Fabio Cumbo, Katherine Do, et al.

    The explosion of microbial omics data has outpaced the ability of many researchers to analyze it, with complex tools and limited computational resources creating barriers to discovery. To address this gap, we present the Microbiology Galaxy Lab: a free, globally accessible, community-supported platform that combines state-of-the-art analytical power with user-friendly accessibility. Supported by the Galaxy and global microbiology communities, this platform integrates over 315 tool suites and 115 curated workflows, enabling comprehensive metabarcoding, (meta)genomic, (meta)transcriptomic, and (meta)proteomic data analysis within a FAIR-aligned environment. It also supports research in the health and infectious disease sectors, as well as in environmental microbiology. The platform's utility is exemplified through various use cases, including antimicrobial resistance tracking, biomarker prediction, microbiome classification, and functional annotation of key microbes. Built on reproducibility and community engagement, it supports creation, sharing, and updating of best-practice workflows. Over 35 tutorials and learning paths empower scientists, fostering an ecosystem that keeps resources at the forefront of microbial science. The Microbiology Galaxy Lab enables collective analysis, democratising research, thereby accelerating discovery across the global microbiology community (microbiology.usegalaxy.org, .eu, .org.au, .fr).


  • DNA extraction from placental, fetal and neonatal tissue at autopsy: what organ to sample for DNA in the genomic era?

    by Admire Matsika, Renee Gallagher, Mark Williams, Christopher Joy, Emma Lowe, Gareth Price, Lachlan Webb, Louise Marquart, Anita Pelecanos, James Harraway, et al.


  • Open Access

    Prostaglandin I2 in the Endosteal Bone Marrow Niche As a Novel Regulator of Hematopoietic Stem Cells

    by Joshua Tay, Jean-Pierre Levesque, Falak Helwani, Gareth Price, Bianca Nowlan, Valerie Barbier, Ingrid G Winkler

    Haematopoietic stem cells (HSCs) are regulated by their immediate microenvironment or niche. The most potent functional HSCs are enriched at the endosteum near the bone, which comprises ~10% of total bone marrow (BM). To identify novel niche factors that regulate HSCs, we performed a gene expression microarray seeking genes that were >2-fold overexpressed in the endosteal BM relative to the central BM. In this screen, we uncovered known essential HSC niche factors overexpressed in the endosteal BM such as Scf, Cxcl12, and Angpt1, which validated our approach. Among the genes overexpressed in the endosteal BM, prostaglandin I2 (PGI2) synthase (Ptgis) was one of the highest enriched genes in the endosteum (>10-fold by qRT-PCR, pPtgis was most abundantly expressed by osteoblasts, followed by mesenchymal stem/progenitor cells and endothelial cells. Ptgis is the sole enzyme responsible for biosynthesis of PGI2, originally discovered as a potent anti-thrombotic and vasodilating agent. PGI2 has no reported roles in HSC regulation in the BM and was chosen as candidate niche factor for further investigation. Due to the extreme lability of PGI2, we employed a clinically approved PGI2 analogue iloprost for all subsequent experiments. In initial experiments where we cultured fluorescence activated cell sorted (FACS) BM lineage- Kit+ Sca-1- (LKS+) haematopoietic stem and progenitor cells (HSPCs) for 7 days in serum free conditions, we found iloprost treatment potently reduced proliferation and differentiation compared to vehicle controls, assessed by flow cytometry phenotyping (p2 enhances HSC function by dampening differentiation. We next sought to determine whether iloprost affects HSC function in vivo. In steady state, low dose 0.1mg/kg iloprost administration to mice for 15 days did not alter BM HSPC phenotypes by flow cytometry nor HSC reconstitution potential in competitive transplants compared to vehicle controls suggesting PGI2 does not alter HSC function in homeostasis. To further test the effect of PGI2 following stress, mice were sub-lethally (6.5 Gy) irradiated or administered pro-inflammatory granulocyte colony stimulating factor (G-CSF) for 3 days. We found low dose iloprost administration partially rescued BM HSC reconstitution potential 21 days following irradiation (p2 protects HSC from stress. To understand the extrinsic mechanisms through which PGI2 regulates HSC in the BM following stress, we performed a HSC homing assay using naïve donors transplanted into 2-day G-CSF administered recipients. Analysis of HSPC homing to the BM at 4 hours post-transplantation revealed ~4-fold greater proportion of LKS+ HSPC homing to the BM of iloprost co-administered recipients compared to vehicle controls (pScf and Cxcl12 expression, which were both partially rescued with iloprost co-administration (p2 protects HSC during stress. In summary, we have identified PGI2 as a novel HSC niche factor abundant in the endosteal BM. PGI2 analogues like Iloprost are well-tolerated and used clinically to treat vascular diseases such as pulmonary arterial hypertension and Raynaud's phenomenon. Our research suggests that PGI2 analogues can be rapidly repurposed in the clinic to improve HSC transplant outcomes and protect against BM failure following acute stressors such as accidental irradiation or inflammation.


  • Application of Whole Genome Sequencing Technology in the Investigation of Genetic Causes of Fetal, Perinatal, and Early Infant Death

    by Jane E Armes, Mark Williams, Gareth Price, Tristan Wallis, Renee Gallagher, Admire Matsika, Christopher Joy, Melanie Galea, Glenn Gardener, Rick Leach, et al.

    Death in the fetal, perinatal, and early infant age-group has a multitude of causes, a proportion of which is presumed to be genetic. Defining a specific genetic aberration leading to the death is problematic at this young age, due to limited phenotype–genotype correlation inherent in the underdeveloped phenotype, the inability to assess certain phenotypic traits after death, and the problems of dealing with rare disorders. In this study, our aim was to increase the yield of identification of a defined genetic cause of an early death. Therefore, we employed whole genome sequencing and bioinformatic filtering techniques as a comprehensive, unbiased genetic investigation into 16 fetal, perinatal, and early infant deaths, which had undergone a full autopsy. A likely genetic cause was identified in two cases (in genes; COL2A1 and RYR1) and a speculative genetic cause in a further six cases (in genes: ARHGAP35, BBS7, CASZ1, CRIM1, DHCR7, HADHB, HAPLN3, HSPG2, MYO18B, and SRGAP2). This investigation indicates that whole genome sequencing is a significantly enabling technology when determining genetic causes of early death.


  • Isolated Ventricular Noncompaction Cardiomyopathy Presenting as Fetal Hydrops at 24 Weeks Gestation

    by Jane E Armes, Lisa Squires, Rohan Lourie, Mark Williams, Renee Gallagher, Gareth Price, Andrew Stubbs, Sigrid Ma Swagemakers, Peter J van der Spek, James Harraway, et al.

    Ventricular noncompaction cardiomyopathy is a rare form of congenital cardiomyopathy with increasing evidence of genetic etiology, especially when presenting in childhood. Fetal presentation is rare. We describe a case of fetal hydrops, presenting at 24 weeks gestation and leading to intrapartum death at 26 weeks gestation. Autopsy examination revealed characteristic features of left ventricular noncompaction. A genetic analysis identified a constellation of variants of unknown significance in MYH6, TNNC1, and MYBPC3, genes known to be important in sarcomeric function. Additionally, the variant in MYBPC3 was homozygous. While this case did not demonstrate a conventional single-gene mutation as the cause of the ventricular noncompaction, a broader genomic investigation revealed several variants in sarcomeric genes which may act synergistically to impact cardiac function.


  • MALDI-TOF MS meets WGS in a VRE outbreak investigation

    by S. Schlebusch, G. R. Price, R. L. Gallagher, V. Horton-Szar, L. D. H. Elbourne, P. Griffin, D. J. Venter, S. O. Jensen, S. J. Van Hal

    The use of MALDI-TOF MS (matrix-assisted laser desorption/ ionization–time of flight mass spectrometry) and WGS (whole genome sequencing) has been described for identification and strain relatedness determination. We describe the complementary use of MALDI-TOF MS and WGS in a VRE (vancomycin-resistant enterococci) outbreak investigation, and discuss some of the challenges with defining strain similarity across these two platforms. Although both assays indicated multiple clusters involved in the outbreak of vancomycin resistant Enterococcus faecium isolates from positive blood cultures of four haematology–oncology patients, the small cohort and discrepancies between findings indicate the limitations of MALDI-TOF MS and the cautious interpretation of MALDI-TOF MS dendrograms during outbreaks. For definitive determination of the evolutionary distance between isolates, WGS can be used.


  • Ovarian Microcystic Stromal Tumor: A Rare Clinical Manifestation of Familial Adenomatous Polyposis

    by Cheng Liu, Renee L. Gallagher, Gareth R. Price, Elizabeth Bolton, Christopher Joy, James Harraway, Deon J. Venter, Jane E. Armes

    Microcystic stromal tumor (MST) is a rare tumor of presumed sex-cord stromal differentiation. We present a case of MST arising within a patient with constitutional 5q deletion syndrome, whose deletion encompassed the APC gene. Genomic analysis of the MST revealed a point mutation in the remaining APC allele, predicted to result in abnormal splicing of Exon 7. Subsequent clinical investigation revealed multiple gastrointestinal polyps qualifying for a diagnosis of familial adenomatous polyposis. This case emphasizes the importance of an aberrant Wnt/β-catenin pathway in the development of MST and adds credence to the inclusion of MST as a rare phenotype of familial adenomatous polyposis. In a search for additional genetic aberrations which may contribute to the development of this rare tumor, genomic analysis revealed a frameshift mutation in FANCD2, a protein which plays a key role in DNA repair. This protein is expressed in human ovarian stromal cells and FANCD2-knockout mice are known to develop sex cord-stromal tumors, factors which further support a possible role of aberrant FANCD2 in the development of MST.